Oxbridge Re Holdings Ltd - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated February 24, 2025, details a material definitive agreement entered into by Oxbridge Re Holdings Limited (the "Company"). The filing reports on a registered direct offering and a private placement of warrants to an institutional investor.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $3.0 million.
- Net Proceeds: Approximately $2.7 million after deducting placement agent fees and estimated offering expenses.
- Securities Issued:
- 705,884 ordinary shares.
- Series A Warrants to purchase up to 529,413 ordinary shares.
- Series B Warrants to purchase up to 882,355 ordinary shares.
- Effective Offering Price: $4.25 per ordinary share and accompanying warrants.
- Placement Agent Fees: 6.0% of gross proceeds plus reimbursement of expenses (legal fees capped at $45,000).
Material Changes and Terms
The Company entered into a Securities Purchase Agreement with an institutional investor. Key terms include:
- Series A Warrants: Immediately exercisable, expire two years from the initial exercise date, with an exercise price of $4.25 per share.
- Series B Warrants: Exercisable on the earlier of shareholder approval or six months from issuance. They expire five years from the initial exercise date. The exercise price is the lower of $5.00 or $4.25 (the latter applies after shareholder approval).
- Lock-Up Provisions: For 60 days post-closing, the Company is restricted from issuing ordinary shares or equivalents, including Variable Rate Transactions, subject to certain exceptions.
- Shareholder Approval: The Company must hold a meeting on or before June 30, 2025, to obtain shareholder approval for the issuance of shares underlying the Series B Warrants at the $4.25 price, as required by Nasdaq rules.
Outlook, Risks, and Contingencies
The filing does not provide specific forward-looking guidance on revenue, profit, or operational outlook. The primary contingency noted is the requirement for shareholder approval by June 30, 2025, to finalize the terms of the Series B Warrants. The Company has agreed to file a registration statement for the resale of shares issuable upon warrant exercise within 60 days of the agreement date.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received.
- Confirm the date and outcome of the shareholder meeting scheduled for or before June 30, 2025, regarding Series B Warrants.
- Review the filed Registration Statement (Form S-3 No. 333-262590) and the specific terms of the Securities Purchase Agreement (Exhibit 10.1) for detailed covenants.
- Monitor future filings for the registration statement covering the resale of shares underlying the Warrants.